Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment
Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on ...
Allurion Technologies’ gastric balloon+GLP1s may become new SOC, says Roth MKM
Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.
Hosted on MSN2mon
Allurion Balloon: A medical innovation to treat obesity without surgery
The Allurion IGB procedure ... Even after a year - despite the balloon no longer being in the stomach - weight loss continued to up to 13.7 per cent of the original body weight.
CNN6d
Allurion Technologies, Inc.
The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including ...
Business Wire29d
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss with the ...
Allurion Technologies balloon data ‘intriguing,’ says Chardan
Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...
Seeking Alpha13d
Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment
Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo ...